1-2 of 2
Douglas Sborov, MD MS
Close
Sort by
Journal Articles

Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 12 Months of Maintenance Therapy

Jonathan L. Kaufman, MD, Jacob P. Laubach, Douglas Sborov, MD MS, Brandi Reeves, MD, Cesar Rodriguez, MD, Ajai Chari, Rebecca W. Silbermann, MD, Luciano J. Costa, MD PhD, Larry D. Anderson, Jr., MD PhD, Nitya Nathwani, MD, Nina Shah, MD, Yvonne A. Efebera, MD MPH, Sara A. Holstein, MDPhD, Caitlin Costello, Andrzej Jakubowiak, MD PhD, Tanya M. Wildes, MD MSCI, Robert Z. Orlowski, MDPhD, Kenneth H. Shain, MD PhD, Andrew J. Cowan, Yana Lutska, PharmD, Padma Bobba, Huiling Pei, PhD, Jon Ukropec, PhD, Jessica Vermeulen, MD PhD, Thomas S. Lin, MD PhD, Paul G. Richardson, MD, Peter M. Voorhees
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-137109
Published: 2020
Journal Articles

Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sagar Lonial, MD FACP, Ajay Nooka, MDMPH, Praneetha Thulasi, MD, Ashraf Z. Badros, MD, Bennie H. Jeng, MD, Natalie S. Callander, MD, Douglas Sborov, MD MS, Brian E. Zaugg, MD, Rakesh Popat, Simona Degli Esposti, MD, Julie Byrne, PhD, Joanna Opalinska, MD PhD, January Baron, MS, Trisha Piontek, BSN, Ira Gupta, MD, Reza Dana, MD MSc, MPH, Asim Farooq, MD, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–27.
https://doi.org/10.1182/blood-2020-140078
Published: 2020